SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 9.99% Stake in SeaStar Medical Holding Corp

Armistice Capital, LLC and Steven Boyd have jointly disclosed a beneficial ownership of 9.99% in SeaStar Medical Holding Corp's common stock as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons,' have filed a Schedule 13G indicating their beneficial ownership in SeaStar Medical Holding Corp.
• As of March 31, 2025, the Reporting Persons beneficially own an aggregate of 1,019,958 shares of SeaStar Medical Holding Corp's Common Stock.
• This ownership represents 9.99% of the total outstanding shares of the class.
• Armistice Capital, LLC, an investment adviser, and Steven Boyd, its managing member, share both voting and dispositive power over all 1,019,958 shares.
• The shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital acts as the investment manager.
• The acquisition of these securities was made in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates a significant institutional investment, which can be seen as a vote of confidence in the company. However, it's a routine disclosure without specific operational or financial news.

Positives

• The disclosure of a significant 9.99% stake by an institutional investor like Armistice Capital may signal confidence in SeaStar Medical Holding Corp's future prospects.
• The investment is stated to be in the ordinary course of business, suggesting a long-term investment strategy rather than an activist intent.

Risks

• The document does not detail specific risks related to SeaStar Medical Holding Corp's operations or financial health, as it is a beneficial ownership filing.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding SeaStar Medical Holding Corp's future performance or strategic direction.

Industry Context

This filing reflects a standard institutional investment disclosure, where an investment firm acquires a significant stake in a publicly traded company. Such disclosures are common in the financial industry and provide transparency regarding large shareholder positions, which can sometimes influence market perception of the company.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may be viewed positively, potentially increasing investor confidence and attracting further investment interest.
• Management: Awareness of a large institutional holder may influence management's strategic decisions and communication with the investment community.

Key Dates

Keywords

SeaStar Medical Holding Corp, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management